培哚普利联合富马酸比索洛尔治疗原发性高血压的临床疗效及其对心率变异性、动脉僵硬度、左心室肥厚的影响  

Clinical Effect of Perindopril Combined with Bisoprolol Fumarate on Essential Hypertension and the Impact on Heart Rate Variability,Arterial Stiffness and Left Ventricular Hypertrophy

作　　者：向东贤 韩英 丁栗 林芳 XIANG Dongxian;HAN Ying;DING Li;LIN Fang(Jinqiu Hospital of Liaoning Province,Shenyang 110011,China)

机构地区：[1]辽宁省金秋医院,辽宁省沈阳市110011

出　　处：《实用心脑肺血管病杂志》2019年第1期100-103,共4页Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease

基　　金：辽宁省科学技术计划项目(2012020121-201)

摘　　要：目的观察培哚普利联合富马酸比索洛尔治疗原发性高血压的临床疗效,并分析其对心率变异性、动脉僵硬度、左心室肥厚的影响。方法选取2016年1月—2018年1月辽宁省金秋医院收治的原发性高血压患者80例,采用随机数字表法分为对照组和观察组,每组40例。对照组患者采用培哚普利治疗,观察组患者采用培哚普利联合富马酸比索洛尔治疗;两组患者均连续治疗4周。比较两组患者治疗前后血压、心率变异性指标〔包括正常RR间期的标准差(SDNN)、相邻RR间期之差的均方根(RMSSD)、相邻RR间期差值超过50 ms的RR间期所占的百分数(PNN50)、高频(HF)、低频(LF)、极低频(VLF)及LF/HF〕、臂踝动脉脉搏波传导速度(baPWV)及左心室肥厚指标〔包括左心室质量指数(LVMI)、左心室舒张末期内径(LVEDD)、左心室后壁厚度(LVPWT)、舒张末期室间隔厚度(IVST)〕,并记录两组患者治疗期间不良反应发生情况。结果 (1)治疗前两组患者收缩压、舒张压比较,差异无统计学意义(P>0.05);治疗后观察组患者收缩压、舒张压低于对照组(P<0.05)。(2)两组患者治疗前SDNN、RMSSD、PNN50、HF、LF、VLF、LF/HF及治疗后SDNN、RMSSD、PNN50比较,差异无统计学意义(P>0.05);观察组患者治疗后LF、VLF、LF/HF低于对照组,HF高于对照组(P<0.05)。(3)观察组患者治疗前后baPWV差值大于对照组(P<0.05)。(4)两组患者治疗前LVMI、LVEDD、LVPWT、IVST及治疗后IVST比较,差异无统计学意义(P>0.05);观察组患者治疗后LVMI低于对照组,LVEDD短于对照组,LVPWT大于对照组(P<0.05)。(5)两组患者治疗期间不良反应发生率比较,差异无统计学意义(P>0.05)。结论培哚普利联合富马酸比索洛尔能有效降低原发性高血压患者血压及动脉僵硬度,改善心率变异性,逆转左心室肥厚,且安全性较高。Objective To observe the clinical effect of perindopril combined with bisoprolol fumarate on essential hypertension,to analyze the impact on heart rate variability,arterial stiffness and left ventricular hypertrophy. Methods Eighty patients with essential hypertension admitted to Jinqiu Hospital of Liaoning Province were enrolled from January 2016 to January 2018,and they were divided into control group and observation group according to random number table method,each with 40 cases. Patients in control group were treated with perindopril,while patients in observation group received perindopril combined with bisoprolol fumarate;both groups continuously treated for 4 weeks. Blood pressure,indicators of heart rate variability (including SDNN,RMSSD,PNN50,HF,LF,VLF and LF/HF),baPWV and indicators of left ventricular hypertrophy (including LVMI,LVEDD,LVPWT and IVST)were compared between the two groups before and after treatment,and incidence of adverse reactions was recorded during treatment. Results (1)There was no statistically significant difference in systolic or diastolic blood pressure between the two groups before treatment(P>0.05),while systolic and diastolic blood pressure in observation group were statistically significantly lower than those in control group after treatment(P<0.05).(2)There was no statistically significant difference in SDNN,RMSSD,PNN50,HF,LF,VLF or LF/HF between the two groups before treatment(P>0.05);after treatment,there was no statistically significant difference in SDNN,RMSSD or PNN50 between the two groups(P>0.05),LF,VLF and LF/HF in observation group were statistically significantly lower than those in control group(P<0.05),while HF in observation group was statistically significantly higher than that in control group(P<0.05).(3)Difference of baPWV before and after treatment in observation group was statistically significantly greater than that in control group(P<0.05).(4)There was no statistically significant difference in LVMI,LVEDD,LVPWT or IVST between the two groups before treatm

关 键 词：高血压 培哚普利 富马酸比索洛尔 心率变异性 动脉僵硬度 左心室肥厚 治疗结果 

分 类 号：R544.1[医药卫生—心血管疾病]